Navigation Links
Hepatitis C Could Infect 800,000 Australians By 2020

It has been proposed by the federal Government to distribute subsidized life-saving hepatitis C drugs, that would benefit nearly 200,000 hepatitis C infected patients in Australia. // A small percentage of the infected individuals (2000) currently receive treatment for their condition. If appropriate steps are not instituted at the earliest, Australia might soon witness a rapid rise in the cases of liver cirrhosis and cancer.

Hepatitis C is a viral disease that is transmitted through contaminated blood. Approximately 25% get rid of the infection while the rest develop a chronic form of the disease. If left unattended, it can progress to liver cirrhosis and liver failure, eventually leading to liver cancer.

As a part of the new plan, patients would now be exempted from taking up a liver biopsy before treatment pegylated interferon can be initiated. A 45 to 90% of patients can have their hepatitis C infection eradicated if interferon therapy is instituted. Liver biopsy is associated with a small amount of risk and is usually painful. This prevents many patients from availing the diagnostic procedure and further treatment.

In addition, the lack of proper available doctors and nurses to is posing a significant challenge to curbing the Hepatitis C epidemic that has now become a public health problem. Effective management of the crisis would not be possible without increasing the number of health care professionals.

'I think this move will significantly reduce the various obstacles in the way of people with hepatitis C accessing treatment. This is a significant breakthrough in terms of trying to ensure not just that people don't get the disease, but if they get it they are treated appropriately so they lose the disease,' said Mr. Abbott, welcoming the proposal.


'"/>




Page: 1

Related medicine news :

1. Vitamin B for Hepatitis
2. Hepatitis G May Boost HIV Survival
3. Cure for Hepatitis B
4. Hepatitis E virus made impotent
5. Sharing injection equipment spreads Hepatitis C
6. Lymphomas Link to Hepatitis C
7. Hepatitis shots is promising
8. Need for Hepatitis Booster Questioned
9. Good News for HIV Patients Also Suffering From Hepatitis C Virus
10. The Link Between Hepatitis B Vaccine And Multiple Sclerosis Questioned
11. The Effectiveness Of Hepatitis B Vaccine Questioned
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2016)... ... 29, 2016 , ... Reltok Nasal Products proudly announces that Boston Medical Products, ... nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product ... a newly patented safety device secured by nasal surgeons onto the floor of the ...
(Date:4/29/2016)... ... 29, 2016 , ... Regenerative Medicine Solutions (RMS) scored 94.8124 out ... earning them second place for Tampa’s Best Places to Work. They were ranked in ... a great accomplishment for our team,” says RMS Human Resources Manager Irene Miller. “We ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... promote their animal line of probiotics, Petbiotics ™, as they fondly call ... of animal rescue groups networking for their non-profit organizations. Animal rescues across the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intellitec Solutions is pleased to ... Dynamics GP for one their long-term care clients. Working together with the clients ... key clinical management systems, and delivered a fully integrated accounting and business-management solution ...
(Date:4/29/2016)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in ... saying it is time to set the record straight. Traditionally, BC and AD has ... possibly be true and offers explanation. , “To start with, the Name of the ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company ... and vaccines for the treatment of cancer & metastatic disease, ... Growth Capital Expo to be held on May 3 ... in Las Vegas, Nevada.  The Company presentation will be ... by Dr. John N. Bonfiglio a TapImmune Board ...
(Date:4/27/2016)... Inc. (Nasdaq: HOLX ) announced today ... quarter ended March 26, 2016.  GAAP diluted earnings ... non-GAAP diluted EPS of $0.47 increased 14.6%.  Revenue ... basis, and 6.3% on a constant currency basis.  ... highlighted by 14.6% growth in non-GAAP EPS," said ...
(Date:4/27/2016)... Avril 2016   ... +5% sur le trimestre, soutenu par une croissance ... Croissance de +16% des ventes aux hôpitaux ... Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur ... aujourd,hui son chiffre d,affaires pour le premier trimestre ...
Breaking Medicine Technology: